Year
2023
-
Maze Therapeutics to Present Phase 1 Results from First-in-Human Trial Evaluating MZE001 as a Potential Oral Treatment for Pompe Disease
-
Travere Therapeutics Announces FDA Accelerated Approval of FILSPARIᵀᴹ (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy
-
COVID-19 Infection Can Increase a Patient’s Risk of New-Onset Diabetes
-
Chiesi Group’s Lamzede Gets FDA Approval for Rare Genetic Disorder
-
Moderna announces interim results from Phase 3 safety and immunogenicity trial of mRNA-1010, vaccine candidate.
-
FDA Accepts Two sNDAs for Merck’s Prevymis
-
Regeneron is off to CHAPLE as FDA starts pozelimab review
-
Modus Therapeutics announces positive topline data from its Phase 1b LPS provocation study evaluating the potential of sevuparin for treatment of sepsis
-
Lagevrio Disappoints in Phase 3 study for Post-Exposure Prevention of COVID-19
-
FDA Approves First Treatment for Geographic Atrophy, Accepts NDA for Same Indication